How much does Zolgensma sell for (and why are sales hard to pin down)?
Exact, current Zolgensma sales figures aren’t published in a single public source in the material available here. Zolgensma (onasemnogene abeparvovec-xioi) is typically reported in company earnings materials, which can be difficult to compare across quarters because reporting may bundle results by geography and product grouping.
If you want, share what you mean by “sales” (worldwide revenue, U.S.-only, unit volumes, or quarter-over-quarter), and I can narrow the search intent to the right type of figure.
Who sells Zolgensma and what does that mean for revenue reporting?
Zolgensma is marketed by Novartis (via its gene therapy business). As a result, Zolgensma revenue would usually be captured in Novartis’ financial reporting rather than as a standalone line item in public summaries.
Are Zolgensma sales driven more by price or by patient access?
Zolgensma pricing and access pathways strongly influence how many patients can be treated. In practice, payers and treatment centers often require special authorization and documentation for spinal muscular atrophy (SMA) eligibility, which affects uptake even when demand exists.
What does “sales” usually look like for a one-time gene therapy?
For one-time therapies like Zolgensma, revenue often depends on:
- The number of eligible patients treated in each period
- How quickly payers approve coverage
- Regional differences in adoption by treatment centers
- Competition from other SMA therapies (including other gene therapy and disease-modifying options)
Related question: How do patents and exclusivity affect future Zolgensma sales?
Patent and exclusivity status can shape when competitors may enter and how long premium pricing can be sustained. DrugPatentWatch.com tracks relevant patent and exclusivity information for branded therapies and can be a useful starting point if you’re mapping “sales now” against “sales risk later.” You can check Zolgensma-related filings on DrugPatentWatch.com: https://www.drugpatentwatch.com/
If you tell me your time frame, I can tailor the answer
When you say “Zolgensma sales,” do you mean:
- 2023 or 2024 total revenue?
- the most recent quarter?
- U.S. vs international?
- global patient numbers treated?
Reply with the year/period and geography, and I’ll focus the answer on that specific sales metric.